← Human Trials & Peer-Reviewed Studies
The role of cystine-glutamate exchange in nicotine dependence in rats and humans.
Plain-language guide to PMID 19103434 (2009): randomized controlled trial of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 19103434
- Journal
- Biological psychiatry
- Year
- 2009
- Study type
- Randomized Controlled Trial
- Authors
- Knackstedt LA et al. (8 authors)
- DOI
- 10.1016/j.biopsych.2008.10.040
What This Study Did, in Plain Language
What Was Tested
Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.
Somatic signs of withdrawal were measured and immunoblotting was performed 12 hours after the last nicotine exposure to determine if the catalytic subunit of the cystine-glutamate exchanger, xCT, or the glial glutamate transporter, GLT-1, were altered in the ventral tegmental area (VTA), nucleus accumbens, prefrontal cortex, or amygdala.
Why It Was Studied
The present study determined if, akin to cocaine, nicotine self-administration in rats induces adaptations in the expression of glutamate transporters and cystine-glutamate exchangers in brain nuclei implicated in reinforcement and if treating cigarette smokers with a drug that restores cystine-glutamate exchange affects the number of cigarettes smoked.
Who Took Part
PubMed indexes the participants as middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, placebo-controlled and pilot.
Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.
It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.
What Was Measured
The subject headings attached to it are Acetylcysteine, Amino Acid Transport System y+, Amygdala, Brain, Carbon Monoxide, Excitatory Amino Acid Transporter 2 and Nicotine.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and pilot study of Therapeutic nicotine (patch, non-peptide).
The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2009 (Biological psychiatry), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.